HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials.

Abstract
Several recent clinical trials have established that reboxetine, a new selective norepinephrine reuptake inhibitor (selective NRI), is effective and safe for the treatment of major depression. However, the effects of reboxetine on specific symptoms of anxiety, agitation, and insomnia have not been reported. Data were obtained from nine short-term, double-blind, randomized clinical trials in patients with major depression. After initial titration, patients received reboxetine 8 to 10 mg per day. The effects on specific HAM-D symptoms of agitation, anxiety, and insomnia were compared between reboxetine-and placebo-treated patients. In addition, the incidence of treatment-emergent agitation, anxiety, and insomnia side effects with reboxetine were examined. Compared with placebo, the proportion of patients with improvement on the HAM-D agitation item and the HAM-D anxiety and insomnia factors from baseline was significantly greater with reboxetine at most assessment intervals. In general, the incidence of agitation-or anxiety-related side effects was comparable with reboxetine and placebo. Although reboxetine was associated with a significant (p < 0.05) increase in treatment-emergent insomnia reported as an adverse effect during the first week of treatment, very few reports of insomnia were made at subsequent evaluations. The incidence of treatment-emergent agitation or anxiety was comparable between treatment groups.
AuthorsStephen M Stahl, Joseph Mendels, Gerri E Schwartz
JournalJournal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 22 Issue 4 Pg. 388-92 (Aug 2002) ISSN: 0271-0749 [Print] United States
PMID12172338 (Publication Type: Comparative Study, Journal Article, Meta-Analysis)
Chemical References
  • Antidepressive Agents
  • Morpholines
  • Reboxetine
Topics
  • Adult
  • Antidepressive Agents (adverse effects, therapeutic use)
  • Anxiety (drug therapy, epidemiology)
  • Confidence Intervals
  • Depressive Disorder, Major (drug therapy, epidemiology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Morpholines (adverse effects, therapeutic use)
  • Psychomotor Agitation (drug therapy, epidemiology)
  • Randomized Controlled Trials as Topic (methods, statistics & numerical data)
  • Reboxetine
  • Sleep Initiation and Maintenance Disorders (drug therapy, epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: